Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 5/20 | 0.69 |
| ▸ | KISS1R | Q969F8 | 14/20 | 0.67 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.62 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379177 | 0.95 | KISS1R (0.67) | CXCR4KISS1RNMUR2NMUR1 | |
| SCHEMBL30186660 | 0.90 | GNRHR (0.67) | CXCR4KISS1RNMUR2NMUR1 | |
| SCHEMBL31683258 | 0.90 | CXCR4 (0.71) | CXCR4KISS1R | |
| SCHEMBL29389088 | 0.88 | CXCR4 (0.65) | CXCR4NMUR2NMUR1 | |
| Kisspeptin-10 SCHEMBL29376534 | 0.88 | KISS1R (0.77) | KISS1R | |
| SCHEMBL30530852 | 0.88 | KISS1R (0.77) | KISS1R | |
| Kisspeptin-10 SCHEMBL15930211 | 0.88 | KISS1R (0.77) | KISS1R | |
| SCHEMBL29379050 | 0.88 | KISS1R (0.77) | KISS1R | |
| Kisspeptin-10 SCHEMBL20865531 | 0.88 | KISS1R (0.77) | KISS1R | |
| SCHEMBL17345398 | 0.88 | KISS1R (0.77) | KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220040253-A1 | Agonists of Human Kisspeptin Receptor for Modulating Sexual Desire | Université de Liège (BE) | 2022-02-10 | — | — | US | claimed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3811080-B1 | IN VITRO METHOD FOR THE DIAGNOSIS OF ECTOPIC PREGNANCY | UNIV CORDOBA (ES) | 2026-02-11 | — | — | EP | disclosed |
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250223580-A1 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | THE BROAD INSTITUTE, INC. | 2025-07-10 | — | — | US | disclosed |
| WO-2025133225-A1 | PHARMACEUTICAL COMBINATION OF PEPTIDE-GLY AND PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) | PAM THERAGNOSTICS GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| US-12338464-B2 | Clonal strains of attenuated vaccinia viruses and methods of use thereof | GENELUX CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| EP-4545553-A2 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | ShangPharma Innovation Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250051763-A1 | METHODS AND SYSTEMS FOR CONDITIONALLY REGULATING GENE EXPRESSION | FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION (PT) | 2025-02-13 | — | — | US | disclosed |
| CN-116535519-A | Fermentation production method of gonadotropin releasing hormone hexamer-kis peptide | 安徽农业大学 | 2023-08-04 | — | — | CN | disclosed |
| US-20230008052-A1 | CLONAL STRAINS OF ATTENUATED VACCINIA VIRUSES AND METHODS OF USE THEREOF | GENELUX CORPORATION | 2023-01-12 | — | — | US | disclosed |
| WO-2022253998-A1 | PEPTIDES WITH MUCIN-BINDING PROPERTIES | UNIVERSITY OF COPENHAGEN (DK) | 2022-12-08 | — | — | WO | disclosed |
| US-20220281989-A1 | GPCR BINDING PROTEINS AND SYNTHESIS THEREOF | Twist Bioscience Corporation | 2022-09-08 | — | — | US | disclosed |
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2022-08-30 | — | — | US | disclosed |
| US-11407837-B2 | GPCR binding proteins and synthesis thereof | Twist Bioscience Corporation (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220242908-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220213142-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-20220040253-A1 | Agonists of Human Kisspeptin Receptor for Modulating Sexual Desire | Université de Liège (BE) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | CXCR4 432/4885KISS1R 2641/4885NMUR2 2031/4885 |
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | KISS1R, VIP, NPY1R | CXCR4 1122/4885KISS1R 1/4885NMUR2 1452/4885 |
| US-20220213142-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | KISS1R, VIP, SSTR3 | CXCR4 563/4885KISS1R 1/4885NMUR2 441/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | CXCR4 1780/4885KISS1R 1227/4885NMUR2 1950/4885 |
| US-20220242908-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | KISS1R, NPY1R, GLP1R | CXCR4 1598/4885KISS1R 1/4885NMUR2 1982/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | CXCR4 432/4885KISS1R 2641/4885NMUR2 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.